View Full Version : [Neurology] Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke

Sun 30th October '16, 10:20pm
An RCT about stroke and the therapy of thrombolysis.

This trial involving predominantly Asian patients with acute ischemic stroke did not show the noninferiority of low-dose alteplase to standard-dose alteplase with respect to death and disability at 90 days. There were significantly fewer symptomatic intracerebral hemorrhages with low-dose alteplase. (Funded by the National Health and Medical Research Council of Australia and others; ENCHANTED ClinicalTrials.gov number, NCT01422616 (http://clinicaltrials.gov/show/NCT01422616).)